

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



12 May 2026

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

### **Change in Board of Directors and Composition of Committees**

---

#### **Appointment of Dr. Andreas Busch as an Independent Director**

This is to inform that the Board of Directors has, by a resolution passed today, approved the appointment of Dr. Andreas Busch (DIN: 11699735) as an Independent Director of the Company for a term of Five (5) consecutive years effective from 12 May 2026, subject to the approval of the shareholders.

The requisite details pertaining to the appointment, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III, are enclosed herewith as [Annexure A](#).

#### **Changes in the Composition of Committees**

This is further to inform that, pursuant to our earlier intimations dated [31 January 2026](#), [04 April 2026](#) and [08 May 2026](#), Ms. Rama Bijapurkar shall retire from the Board with effect from 20 May 2026 upon completion of her term as an Independent Director. Accordingly, the Board of Directors has, by a resolution passed today, approved the appointment of Ms. Satyavati Berera (DIN: 05002709) as a member of the Audit Committee and the Risk Management Committee, with effect from 12 May 2026.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



### Annexure A

#### Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details
1	Name	Dr. Andreas Eugen Busch (DIN: 11699735)
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
3	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment;	Appointment as Independent Director for a term of five (5) consecutive years effective from 12 May 2026 subject to shareholders' approval
4	Brief profile (in case of appointment);	<a href="#">Annexure A1</a>
5	Disclosure of relationships between directors (in case of appointment of a director).	Dr. Andreas Eugen Busch is not related to any Director, Key Managerial Personnel or promoter of the Company and does not have any inter se relationship with any of the Directors of the Company
6	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/2018/ 24, both dated 20 June 2018	Dr. Andreas Eugen Busch is not debarred from holding the office of Director on account of any order of SEBI or any other such authority.

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



### Annexure A1

#### Brief Profile of Dr. Andreas Eugen Busch



Dr. Andreas Eugen Busch, PhD, is presently Chief Innovation Officer of Absci and is responsible for leading R&D, technical operations, and driving both Absci's internal and partner programs. Dr. Busch brings substantial R&D expertise to Sun Pharmaceutical's Board as a world-renowned leader in drug discovery and has led R&D efforts for some of the globe's top pharma companies including Sanofi, Bayer, and Shire. His leadership has resulted in over 15 commercial drugs starting from bench to FDA approval with several more in late-stage clinical development. He holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany, where he also received his PhD in Pharmacology.